Chemoinformaics analysis of 1,2,3,4-TETRAHYDRO-BETA-CARBOLINE
| Molecular Weight | 172.231 | nRot | 0 |
| Heavy Atom Molecular Weight | 160.135 | nRig | 15 |
| Exact Molecular Weight | 172.1 | nRing | 3 |
| Solubility: LogS | -1.29 | nHRing | 2 |
| Solubility: LogP | 1.293 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 25 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 1 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 11 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 9 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 10 |
| nHA | 1 | APOL | 28.5715 |
| nHD | 2 | BPOL | 13.1785 |
| QED | 0.623 |
| Synth | 2.294 |
| Natural Product Likeliness | -0.003 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.903 |
| HIA | 0.006 |
| CACO-2 | -5.07 |
| MDCK | 0.0000185 |
| BBB | 0.897 |
| PPB | 0.246252 |
| VDSS | 2.751 |
| FU | 0.58256 |
| CYP1A2-inh | 0.743 |
| CYP1A2-sub | 0.905 |
| CYP2c19-inh | 0.203 |
| CYP2c19-sub | 0.287 |
| CYP2c9-inh | 0.009 |
| CYP2c9-sub | 0.489 |
| CYP2d6-inh | 0.902 |
| CYP2d6-sub | 0.912 |
| CYP3a4-inh | 0.097 |
| CYP3a4-sub | 0.354 |
| CL | 8.251 |
| T12 | 0.704 |
| hERG | 0.309 |
| Ames | 0.164 |
| ROA | 0.9 |
| SkinSen | 0.883 |
| Carcinogencity | 0.064 |
| EI | 0.091 |
| Respiratory | 0.986 |
| NR-Aromatase | 0.007 |
| Antiviral | No |
| Prediction | 0.676601 |